ArticleCurrent treatment options in cardiovascular medicine2009
Low-density lipoprotein apheresis as a treatment option for hyperlipidemia.
Article in Current treatment options in cardiovascular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01138371 (Inflammatory and Lipid Markers Pre- and Post-LDL Apheresis), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inflammatory and Lipid Markers Pre- and Post-LDL Apheresis: A Multicenter Experience
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia.Journal of the American Heart Association · 2016Pooled it
- Prospective multicentre study of the effect of voluntary plasmapheresis on plasma cholesterol levels in donors.Vox sanguinis · 2013Trial
- Recommendations for the management of patients with familial hypercholesterolemia.Current atherosclerosis reports · 2015Review
- Current Treatment of Familial Hypercholesterolaemia.European cardiology · 2014Review
- Familial hypercholesterolemia: A review.Annals of pediatric cardiology · 2014Review
- Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia.International urology and nephrology · 2011Article
- Coronary insufficiency in children: Review of literature and report of a rare case with unknown aetiology.Journal of the Saudi Heart Association · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data support the relevance of blood cholesterol levels, particularly high levels of low-density lipoprotein (LDL), in the pathogenesis and progression of atherosclerosis. A strong and continuous relationship between dyslipidemia and vascular morbidity and mortality has been established. The initial approach to treating dyslipidemia consists of lifestyle modifications followed by pharmacologic therapy, usually beginning with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Some patients with familial hypercholesterolemia (FH) fail to achieve their LDL goal despite aggressive pharmacologic therapy. In certain cases, LDL apheresis may be an effective therapeutic option. In the United States, LDL apheresis is approved for homozygous FH patients with an LDL cholesterol level >/= 500 mg/dL. For patients with heterozygous FH, LDL apheresis may be offered if their LDL is >/= 300 mg/dL, or >/= 200 mg/dL with known coronary artery disease, despite maximum medical treatment. This review focuses on the principles and methods of LDL apheresis, its potential benefit in clinical care, and its current indications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.